

Regen Holdings / RegenHealth Physicians

Physician-Led Regenerative Medicine Platform — Stem Cells, Exosomes, Peptides & Longevity

\$2.4M ANNUALIZED RUN RATE	\$12K AVG. CASE VALUE	60–70% GROSS MARGIN	100% Cash-Pay ZERO INSURANCE FRICTION	4 Locations NYC FLAGSHIP • HEALSPACE LIC • SLC • SEATTLE
--------------------------------------	---------------------------------	-------------------------------	---	--

THE PROBLEM

Over 30 million Americans suffer from osteoarthritis. The current care pathway funnels patients toward cortisone injections, opioid management, and surgical joint replacement — a \$75B+ orthopedic surgery market built on procedures with long recoveries, high complication rates, and limited biological repair. Patients seeking non-surgical alternatives face a fragmented, under-regulated landscape of clinics with inconsistent cell sourcing, no outcome tracking, and no standardized protocols.

OUR SOLUTION

RegenHealth Physicians is a physician-founded, cash-pay regenerative medicine platform delivering umbilical cord-derived stem cell therapy, exosome protocols, MUSE cells, and prescription peptide programs. We treat orthopedic pain (joints, spine), neurological conditions (TBI, neuropathy), sexual health, aesthetics, hair restoration, and systemic longevity — with two NYC locations (Madison Avenue flagship and HealSpace LIC), Salt Lake City, and Seattle opening next.

Every batch of biologics is sourced from FDA-registered, cGMP-compliant US tissue banks with Certificates of Analysis verifying 97%–99% live cell viability. Our proprietary **Praevorium™** platform (in development with technology partner **Auglabs**) will connect clinical, operational, financial, lab, wearable, and patient-reported data — enabling optimized treatment protocols, performance measurement, and AI-powered clinical intelligence across all locations.

TARGET MARKET & CUSTOMER

Primary: Cash-pay patients ages 40–70 with chronic joint pain, spinal degeneration, or post-surgical candidates seeking alternatives to replacement surgery. Average HHI \$200K+.
Secondary: High-net-worth executives and athletes seeking proactive longevity protocols — IV stem cell infusions, peptide optimization, and biological age reversal.
TAM: \$25B+ regenerative medicine market (Grand View Research, projected 2030), growing at 14.2% CAGR.

BUSINESS MODEL

100% cash-pay — zero insurance dependency. Tiered packaging from entry protocols (\$3,999) through Elite Concierge (\$42,000) and Total Transformation (\$35,000). Monthly membership programs (\$599–\$2,200/mo) drive recurring revenue. 60–70% gross margins with ~\$12K average case value. Revenue scales with location count on a repeatable, capital-efficient buildout model.

CLINICAL RESULTS & PATIENT OUTCOMES

100+ knees treated with a 90% success rate — patients consistently report reduced baseline pain, improved range of motion, less morning stiffness, and better tolerance of daily activities. **4.9-star Google rating.**

"I traveled from Vancouver, Canada dealing with chronic back pain and chronic knee pain. After IV therapy plus back and knee injections, I feel like a completely new person — I finally have my life back."

— RegenHealth patient, bilateral knee + spine protocol

Patients commonly report: pain reduction within 4–8 weeks, continued improvement over 3–6 months, return to full activity including sports and exercise, and reduced or eliminated dependence on pain medication.

TRACTION & VALIDATION


METRIC	DATA
July 2026 Revenue	\$202,428 (monthly record)
H1 2026 Revenue	\$412,252
Annualized Run Rate	~\$2.4M
Gross Profit (H1)	\$196,216
Avg. Case Value	~\$12,000
Locations	NYC Flagship + HealSpace LIC + SLC + Seattle (opening)
Patient Database	5,000+
Clinical Track Record	100+ knees, 90% success rate
Google Rating	4.9 stars

LEADERSHIP

- ▶ **Dr. Ajit Dhaliwal, MD, MBA** — Founder & CEO. Mount Sinai residency, Royal College of Surgeons. Previously built and exited Momentum Healthcare Staffing.
- ▶ **Dr. Ravneet Dhaliwal, MD** — CMO. Board-Certified Family & Obesity Medicine. Oversees all clinical protocols and quality.
- ▶ **Irene Kim, PA-C** — Clinical Director. Oversees all patient procedures and clinical pathways.
- ▶ **Mark Anderson** — COO. Praevorium™ platform architect.
- ▶ **Will Michael** — Chief Strategy Officer. Growth and expansion strategy.
- ▶ **Gabrielle Carreiro** — Chief Marketing Officer. Patient acquisition, brand development, and multi-channel demand generation.

CAPITAL RAISE

Raising **\$2.5M via SAFE** at a **\$10M valuation cap** with 20% discount (Reg D 506(b)).



What We're Seeking

Strategic investors, physician network introductions, health system pilot partnerships, and distribution relationships that accelerate our expansion from 4 locations to a national footprint — positioning for franchise launch thereafter.